Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B15/EV-304 perioperative enfortumab vedotin + pembrolizumab versus neoadjuvant gemcitabine + cisplatin in muscle-invasive bladder cancer
MOH_2021-08-23_010218Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin, pembrolizumab, gemcitabine and cisplatin in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC), sponsored by Merck & Co. Started Jun 2021; status: active, not recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2021-08-23_010218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-23_010218.